Publications by authors named "Peter K Working"

Claim this Profile
P
Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease.
Andrew A Badachhape, Peter K Working, Mayank Srivastava, Prajwal Bhandari, Igor V Stupin

Sci Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses.
Peter K Working, Andy Lin, Flavia Borellini

Oncogene· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
David M Vail, Michael A Amantea, Gail T Colbern, Francis J Martin, Ralf A Hilger, Peter K Working

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
William C Zamboni, Anne C Gervais, Merrill J Egorin, Jan H M Schellens, Elleanor G Zuhowski, Peter K Working

Cancer Chemother Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
David M Vail, Ilene D Kurzman, Phyllis C Glawe, Maura G O'Brien, Ruthanne Chun, Peter K Working

Cancer Chemother Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis